Karen Andersen, Anna Bonomi, Damien Conover, Steven Pearson
Join Morningstar, Sustainalytics and the Institute for Clinical and Economic Review (ICER) to discuss the methodology in application to a core risk facing the biopharma group: new U.S. government policies aimed at reducing drug pricing to increase access for patients.
Our esteemed panel will discuss their findings from Morningstar's latest research paper, Biopharma ESG Risks from U.S. Pricing doesn't sway our valuation, and:
* How ICER recommendations may influence pricing risks for pharma and biotech companies
* Sustainalytics’ ESG Risk Rating, with a focus on the exposure dimension of access to basic services Material ESG Issues.
* Integration of ESG within Morningstar’s equity research, with regards to the ICER analysis
Karen Andersen, Strategist, Equity and Credit Analysis, Morningstar
Anna Bonomi, Manager, Healthcare & Chemicals Research, Sustainalytics
Damien Conover, Director of Equity Strategy, Morningstar
Steven Pearson, President, Institute for Clinical and Economic Review (ICER)